Astellas Pauses Dosing of AT132 in ASPIRO Clinical Trial for the Treatment of X-linked Myotubular Myopathy
Shots:
- Astellas discontinue the dosing in the ASPIRO trial that evaluates AT132 in 24 participants (7 at the 1.3x1014 vg/kg dose and 17 at the 3.5x1014 vg/kg dose) with XLMTM. The participant has a history of intermittent cholestasis
- The discontinuation is due to serious AEs in a study that demonstrated abnormal LFTs in patients who received a low dose of AT132. Additionally- 3 patients develops progressive cholestatic hepatitis & liver failure who treated at 3.5x1014 vg/kg dose
- In Dec’20- FDA lifted the hold after reviewed the modifications to ASPIRO trial protocol including a reduction of dosing. AT132 has received RMAT- RPD designation- FTD & ODD from the FDA while PRIME & ODD from EMA
| Ref: Astellas | Image: Astellas
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com